LIVE
Home
Politics
Business
Opinion
Technology
Lifestyle
Entertainment
Video
Eisai starts trials for a second Alzheimer's drug a day after Biogen failure wiped $18B off its value
Business
March 22, 2019
This article is being updated.
Previous article: Tiffany shares bounce back as CEO touts growth opportunities
Prev
Next article: Dow futures point to slightly lower open as growth concerns persist
Next
via
CNBC
March 22nd 2019
MixedTimes.com
Business
Eisai starts trials for a second Alzheimer's drug a day after Biogen failure wiped $18B off its value
Home
Politics
Business
Opinion
Technology
Lifestyle
Entertainment
Video